New drug combo aims to tackle recurrent brain lymphomas

NCT ID NCT05681195

Recruiting now Disease control Sponsor: Baptist Health South Florida Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether a combination of two drugs, zanubrutinib and pemetrexed, can safely control or shrink brain lymphomas that have come back or not responded to treatment. About 15 participants will receive the drugs in cycles, followed by maintenance therapy with zanubrutinib alone. The study will measure how well the tumors respond and track side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (Brukinsa) and pemetrexed (Alimta)
What this could lead to: If successful, this combination could offer a new treatment option for people with hard-to-treat CNS lymphomas that have come back or not responded to prior therapy.
What could go wrong: This is a small, early-phase trial with only 15 participants, so results may not apply broadly. The drugs can cause side effects, and the cancer may still progress or recur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm primary central nervous system lymphoma Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA REFRACTORY CANCER RELAPSED CANCER SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA

Contacts and locations

Locations

Miami Cancer Institute at Baptist Health, Inc.
RECRUITING

Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.